A big deal after various exchanges between companies

Hanmi-MSD·Sanofi, Yuhan-Behringer·Gilead

Various exchanges such as business partnership ahead of'technology transfer'

Big Deal (License Out/LO) of the traditional pharmaceutical companies show that there have been various exchanges in the past.

 

Looking at the recently established Hanmi and Yuhan’s technology transfer partners, it was because there were exchanges such as joint promotion in the past.

 

It was that exchanges in the past led to exchanges between research institutes of both companies, and even technology transfer.

 

Hanmi transferred NASH (non-alcoholic steatohepatitis) treatment, Efinopegdutide (HM12525A) to MSD USA at a scale of ₩1 trillion (down payment of ₩12 billion).

 

It is an analysis that both companies' past ties were involved in the technology export contract.

 

The relationship between Hanmi and MSD goes back to 2009.

 

At the time, the two companies signed a contract to export the hypertensive treatment drug Amosartan to over 50 countries under the brand 'Cozaar XQ'.

 

In 2016, the two companies signed Rosuzet's global export contracts in 23 countries, followed by Mexico this June.

 

An official at a securities company said, “We know that Hanmi has been working with MSD for several years to naturally exchange with the research institutes.

 

There are more and more cases where the reliability accumulated from small exchanges extends to technology transfer”.

 

The 2015 large-scale technology transfer agreement between Hanmi and Sanofi is similar.

 

In 2013, the two companies jointly developed a high blood pressure/hyperlipidemic drug, Rovelito.

 

It covers everything from product development to launch and marketing.

 

Although there has been a change in the relationship between the two companies, including Sanofi's return of rights, there is no disagreement that past exchanges had a positive effect on LO.

 

Small exchanges among Yuhan and Beringer-Gilliard led to big deal Yuhan Corporation is a similar case.

 

Yuhan exported the pre-clinical (animal) NASH therapeutic substances to Beringer Ingelheim in July last year for a total of ₩1 trillion ($870 million).

 

It is a scale that competes for the level among the pre-clinical license agreements in the domestic pharmaceutical industry.

 

The contract amount is $40 million (about ₩45 billion).

 

In 2010, Yuhan entered into a co-promotional agreement with Behringer’s Twynsta, since then, additional treatments for diabetes treatment drugs, Trajenta and Jardiance, are underway.

 

In the early stages, partnerships were expanded as the performance of early joint sale items improved.

 

The relationship between the two companies led to exchanges between research institutes.

 

Based on the confidentiality agreement, they are sharing their research content with each other.

 

In this process, in this process, it is known that exchanges with Yuhan's NASH treatment have also occurred.

 

This is the same as the big deal between Yuhan and Gilead that occurred in January of the same year.

 

Yuhan transferred another NASH therapeutic substance to Gilead Sciences at the time of US$785 million (₩882.3 billion).

 

The down payment is $15 million (about ₩16.8 billion).

 

This case was conducted in the phase of candidate substance discovery.

 

It turns out that it was impossible without the exchange between the two companies.

 

In 2012, Yuhan signed a co-promotional contract with Gilead's hepatitis B treatment drug, 'Viread'.

 

Since 2017, it has been jointly selling various items such as hepatitis C treatment 'Sovaldi' and 'Harvoni', and HIV/AIDS treatment 'Stribild' and 'Genvoya'.